Active Clinical Trials at OOS
All Clinical Trials
Revolution Med
Tumor site:
Pancreatic
Description:
This Expanded Access Program (EAP) is intended to provide daraxonrasib to eligible adult patients with previously treated metastatic pancreatic adenocarcinoma, who have no comparable or satisfactory alternative therapy and are unable to participate in an ongoing daraxonrasib clinical trial.
More info:
Notes:
Expanded Access Program; NCT07573215
Oracle
Tumor site:
Solid Tumors
Description:
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for recurrence detection and explore its value in a healthcare environment subject to cost containment.
More info:
Notes:
Sponsor: Guardant; NCT05059444
Xalience
Tumor site:
Prostate
Description:
The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).
More info:
Notes:
Sponsor: Amgen; NCT07213674
BeOne
Tumor site:
Gastric/GEJ
Description:
This study is designed to assess the levels of drug exposure following treatment with tislelizumab administered as a subcutaneous (SC) injection compared to intravenous infusion (IV) as first-line therapy in adults with gastric or gastroesophageal junction (GEJ) that is locally advanced and cannot be surgically removed or has spread from the stomach to other areas of the body. Approximately 351 patients will be participating in this study. The study is composed of a screening period, a treatment period, and a follow-up period.
More info:
Notes:
Sponsor: BeOne Medicines; NCT07043400
ASC4REAL-2
Tumor site:
CML
Description:
This is a non-interventional, prospective, observational single arm study describing the real-world effectiveness, tolerability, adherence, Healthcare Resource Utilization (HCRU) and Patient-Reported Outcome (PRO) data of asciminib in patients with Ph+ Chronic Myelogenous Leukemia - Chronic Phase (CML-CP) previously treated with ≥2 Tyrosine Kinase Inhibitor (TKIs) in routine clinical practice in Kingdom of Saudi Arabia.
More info:
Notes:
Sponsor: Novartis; NCT06684964
Adjuvant Wider
Tumor site:
Breast
Description:
The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBCFS), in a close to clinical practice patient population with HR-positive (HR+), HER2-negative (HER2-), Anatomic Stage Group III, IIB, and a subset of Stage IIA Early Breast Cancer (EBC).
More info:
Notes:
Sponsor: Novartis; NCT05827081
Elegant
Tumor site:
Breast
Description:
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.
More info:
Notes:
Sponsor: Stemline Therapeutics, Inc.; NCT06492616
Kandela-302
Tumor site:
Breast
Description:
The purpose of this study is to investigate the efficacy and safety of BGB-43395 in combination with letrozole compared with investigator's choice of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) in combination with letrozole in patients with advanced or metastatic hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer (BC) who have not received prior systemic treatment for advanced or metastatic disease.
More info:
Notes:
Sponsor: BeOne Medicines; NCT07492641
Rosetta Breast-01
Tumor site:
Breast
Description:
This is a Phase III trial where participants will be randomized to two treatment groups, which means participants will be assigned by equal chance to a treatment group. This trial will be double-blinded, which means neither the participants nor the trial doctors will know which of the two treatments the participants actually receive. Participants will receive either the trial drug with chemotherapy or placebo (which looks like the trial drug but does not have any drug in it) with chemotherapy.
More info:
Notes:
Sponsor: BioNTech SE; NCT07173751
BF-1
Tumor site:
Lung
Description:
The purpose of this study is to collect and analyze blood samples for the evaluation of a novel cell-free DNA (cfDNA) fragmentation analysis platform. The platform utilizes machine learning algorithms to assess cfDNA fragmentation patterns and compare them to reference populations with and without cancer. This analysis aims to support the development and validation of a non-invasive method for early cancer detection and risk stratification.
Notes:
Sponsor: Aurora Research Institute
Gemini NSCLC
Tumor site:
Lung
Description:
GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance with the goals of identifying the molecular evolution of lung cancer with standard of care therapy, and determining the utility of ctDNA dynamics to predict risk of recurrence and therapeutic outcomes.
More info:
Notes:
Sponsor: Tempus; NCT05236114
Krystal-7
Tumor site:
Lung
Description:
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment.
The Phase 3 portion of the study compares the efficacy of adagrasib in combination with pembrolizumab versus pembrolizumab in patients with unresectable, locally advanced or metastatic squamous or nonsquamous NSCLC with KRAS G12C mutation and PD-L1 TPS >=50% and who are candidates for first line treatment.
More info:
Notes:
Sponsor: Mirati Therapeutics Inc.; NCT04613596
Ovation-23-001
Tumor site:
Lung
Description:
The purpose of this study is to collect blood samples from a large number of individuals with cancer to create a database for researchers to use in future studies. Researchers may use this database to discover new ways to detect and treat cancer and other diseases. Future studies may use stored blood samples to discover how genes affect health and disease.
More info:
Notes:
Sponsor: Ovation.io, Inc.; NCT06369441
Page 1 of
Page: